Recherchemedicale.com
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérocycliques avec 4 noyaux ou plus
Ergolines
Ergolines : Questions médicales fréquentes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ergolines : Questions médicales les plus fréquentes",
"headline": "Ergolines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ergolines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-05",
"dateModified": "2024-12-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ergolines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Composés hétérocycliques avec 4 noyaux ou plus",
"url": "https://recherchemedicale.com/mesh/D006576",
"about": {
"@type": "MedicalCondition",
"name": "Composés hétérocycliques avec 4 noyaux ou plus",
"code": {
"@type": "MedicalCode",
"code": "D006576",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cabergoline",
"alternateName": "Cabergoline",
"url": "https://recherchemedicale.com/mesh/D000077465",
"about": {
"@type": "MedicalCondition",
"name": "Cabergoline",
"code": {
"@type": "MedicalCode",
"code": "D000077465",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.197"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ergométrine",
"alternateName": "Ergonovine",
"url": "https://recherchemedicale.com/mesh/D004874",
"about": {
"@type": "MedicalCondition",
"name": "Ergométrine",
"code": {
"@type": "MedicalCode",
"code": "D004874",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.262"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Méthylergométrine",
"alternateName": "Methylergonovine",
"url": "https://recherchemedicale.com/mesh/D008755",
"about": {
"@type": "MedicalCondition",
"name": "Méthylergométrine",
"code": {
"@type": "MedicalCode",
"code": "D008755",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.262.538"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Lisuride",
"alternateName": "Lisuride",
"url": "https://recherchemedicale.com/mesh/D008090",
"about": {
"@type": "MedicalCondition",
"name": "Lisuride",
"code": {
"@type": "MedicalCode",
"code": "D008090",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.560"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide lysergique",
"alternateName": "Lysergic Acid",
"url": "https://recherchemedicale.com/mesh/D008237",
"about": {
"@type": "MedicalCondition",
"name": "Acide lysergique",
"code": {
"@type": "MedicalCode",
"code": "D008237",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.572"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Lysergide",
"alternateName": "Lysergic Acid Diethylamide",
"url": "https://recherchemedicale.com/mesh/D008238",
"about": {
"@type": "MedicalCondition",
"name": "Lysergide",
"code": {
"@type": "MedicalCode",
"code": "D008238",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.572.522"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Métergoline",
"alternateName": "Metergoline",
"url": "https://recherchemedicale.com/mesh/D008711",
"about": {
"@type": "MedicalCondition",
"name": "Métergoline",
"code": {
"@type": "MedicalCode",
"code": "D008711",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.630"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Méthysergide",
"alternateName": "Methysergide",
"url": "https://recherchemedicale.com/mesh/D008784",
"about": {
"@type": "MedicalCondition",
"name": "Méthysergide",
"code": {
"@type": "MedicalCode",
"code": "D008784",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.689"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nicergoline",
"alternateName": "Nicergoline",
"url": "https://recherchemedicale.com/mesh/D009530",
"about": {
"@type": "MedicalCondition",
"name": "Nicergoline",
"code": {
"@type": "MedicalCode",
"code": "D009530",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.730"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Pergolide",
"alternateName": "Pergolide",
"url": "https://recherchemedicale.com/mesh/D010479",
"about": {
"@type": "MedicalCondition",
"name": "Pergolide",
"code": {
"@type": "MedicalCode",
"code": "D010479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.800"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Ergolines",
"alternateName": "Ergolines",
"code": {
"@type": "MedicalCode",
"code": "D004873",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yongpeng Yao",
"url": "https://recherchemedicale.com/author/Yongpeng%20Yao",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China."
}
},
{
"@type": "Person",
"name": "Chunyan An",
"url": "https://recherchemedicale.com/author/Chunyan%20An",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China."
}
},
{
"@type": "Person",
"name": "Declan Evans",
"url": "https://recherchemedicale.com/author/Declan%20Evans",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry and Biochemistry , University of California , Los Angeles California 90095 , United States."
}
},
{
"@type": "Person",
"name": "Weiwei Liu",
"url": "https://recherchemedicale.com/author/Weiwei%20Liu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China."
}
},
{
"@type": "Person",
"name": "Wei Wang",
"url": "https://recherchemedicale.com/author/Wei%20Wang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Budget impact analysis of cabergoline for medical treatment of Cushing's disease in Brazil.",
"datePublished": "2024-07-30",
"url": "https://recherchemedicale.com/article/39420893",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.20945/2359-4292-2023-0311"
}
},
{
"@type": "ScholarlyArticle",
"name": "Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy.",
"datePublished": "2022-12-13",
"url": "https://recherchemedicale.com/article/36511080",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/echo.15506"
}
},
{
"@type": "ScholarlyArticle",
"name": "Outcome of Dopamine Agonist Therapy Withdrawal in Children with Prolactinomas.",
"datePublished": "2022-05-24",
"url": "https://recherchemedicale.com/article/35609555",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000525226"
}
},
{
"@type": "ScholarlyArticle",
"name": "Resistant prolactinomas: a case series of 26 patients.",
"datePublished": "2022-05-23",
"url": "https://recherchemedicale.com/article/35604631",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12020-022-03080-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://recherchemedicale.com/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://recherchemedicale.com/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérocycliques avec 4 noyaux ou plus",
"item": "https://recherchemedicale.com/mesh/D006576"
},
{
"@type": "ListItem",
"position": 5,
"name": "Ergolines",
"item": "https://recherchemedicale.com/mesh/D004873"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ergolines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ergolines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-01-23",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ergolines",
"description": "Comment diagnostiquer une intoxication aux ergolines ?\nQuels tests sont utilisés pour évaluer l'effet des ergolines ?\nQuels symptômes indiquent un surdosage d'ergolines ?\nComment différencier les effets des ergolines des autres médicaments ?\nQuels critères cliniques sont utilisés pour le diagnostic ?",
"url": "https://recherchemedicale.com/mesh/D004873?page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ergolines",
"description": "Quels sont les symptômes courants des ergolines ?\nLes ergolines provoquent-elles des effets secondaires ?\nComment les ergolines affectent-elles le système nerveux ?\nLes ergolines causent-elles des problèmes cardiovasculaires ?\nQuels symptômes psychologiques sont associés aux ergolines ?",
"url": "https://recherchemedicale.com/mesh/D004873?page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ergolines",
"description": "Comment prévenir l'intoxication aux ergolines ?\nQuelles précautions prendre lors de l'utilisation d'ergolines ?\nLes femmes enceintes doivent-elles éviter les ergolines ?\nComment sensibiliser sur les risques des ergolines ?\nLes interactions médicamenteuses peuvent-elles être évitées ?",
"url": "https://recherchemedicale.com/mesh/D004873?page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ergolines",
"description": "Comment traiter une intoxication aux ergolines ?\nQuels médicaments sont utilisés pour contrer les effets des ergolines ?\nY a-t-il des traitements spécifiques pour les effets secondaires ?\nComment gérer les effets à long terme des ergolines ?\nLes ergolines nécessitent-elles un sevrage ?",
"url": "https://recherchemedicale.com/mesh/D004873?page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ergolines",
"description": "Quelles sont les complications possibles des ergolines ?\nLes ergolines peuvent-elles causer des maladies chroniques ?\nComment les ergolines affectent-elles la santé mentale ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme des ergolines ?",
"url": "https://recherchemedicale.com/mesh/D004873?page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ergolines",
"description": "Quels sont les facteurs de risque d'intoxication aux ergolines ?\nLes personnes âgées sont-elles plus à risque ?\nL'usage concomitant d'autres médicaments augmente-t-il le risque ?\nLes antécédents de troubles mentaux sont-ils un facteur de risque ?\nLe mode de vie influence-t-il le risque d'intoxication ?",
"url": "https://recherchemedicale.com/mesh/D004873?page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux ergolines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical et des tests sanguins pour détecter les ergolines."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'effet des ergolines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests neurologiques et psychologiques peuvent être réalisés pour évaluer l'effet des ergolines."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un surdosage d'ergolines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des hallucinations, des nausées et des troubles cardiaques peuvent indiquer un surdosage."
}
},
{
"@type": "Question",
"name": "Comment différencier les effets des ergolines des autres médicaments ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une analyse des antécédents médicaux et des interactions médicamenteuses aide à cette différenciation."
}
},
{
"@type": "Question",
"name": "Quels critères cliniques sont utilisés pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent l'évaluation des symptômes neurologiques et psychiatriques associés aux ergolines."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des ergolines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des vertiges, des nausées, des hallucinations et des troubles de la mémoire."
}
},
{
"@type": "Question",
"name": "Les ergolines provoquent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des troubles gastro-intestinaux et des réactions allergiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les ergolines affectent-elles le système nerveux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des modifications de l'humeur, des troubles cognitifs et des hallucinations."
}
},
{
"@type": "Question",
"name": "Les ergolines causent-elles des problèmes cardiovasculaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des vasoconstrictions et des troubles du rythme cardiaque."
}
},
{
"@type": "Question",
"name": "Quels symptômes psychologiques sont associés aux ergolines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'anxiété, la dépression et des hallucinations peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'intoxication aux ergolines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'usage non médical et suivre les prescriptions médicales peut prévenir l'intoxication."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de l'utilisation d'ergolines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est important de suivre les doses prescrites et de consulter un médecin en cas d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles éviter les ergolines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes enceintes doivent éviter les ergolines en raison des risques pour le fœtus."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser sur les risques des ergolines ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et des consultations médicales peuvent sensibiliser aux risques."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses peuvent-elles être évitées ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en informant le médecin de tous les médicaments pris, les interactions peuvent être évitées."
}
},
{
"@type": "Question",
"name": "Comment traiter une intoxication aux ergolines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'arrêt du médicament, des soins de soutien et parfois des antidotes spécifiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour contrer les effets des ergolines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les antipsychotiques peuvent être utilisés pour traiter les effets indésirables."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les effets secondaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements symptomatiques comme des antiémétiques peuvent être administrés."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets à long terme des ergolines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière et un suivi psychologique peuvent aider à gérer les effets à long terme."
}
},
{
"@type": "Question",
"name": "Les ergolines nécessitent-elles un sevrage ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un sevrage progressif est recommandé pour éviter des symptômes de sevrage sévères."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des ergolines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles cardiovasculaires, neurologiques et psychiatriques graves."
}
},
{
"@type": "Question",
"name": "Les ergolines peuvent-elles causer des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une utilisation prolongée peut entraîner des maladies chroniques comme la fibrose pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment les ergolines affectent-elles la santé mentale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent exacerber des troubles mentaux préexistants et provoquer des psychoses."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme des ergolines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des troubles neurologiques persistants et des problèmes cardiovasculaires chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'intoxication aux ergolines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'usage récréatif, les antécédents médicaux et les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent être plus sensibles aux effets des ergolines en raison de comorbidités."
}
},
{
"@type": "Question",
"name": "L'usage concomitant d'autres médicaments augmente-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'usage concomitant d'autres médicaments peut augmenter le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les antécédents de troubles mentaux sont-ils un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de troubles mentaux augmentent le risque de complications liées aux ergolines."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque d'intoxication ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie à risque, comme la consommation de drogues, augmente le risque d'intoxication."
}
}
]
}
]
}
The aim of this study was to estimate the budget impact of adding cabergoline to the Brazilian Unified Health System (SUS) formulary for the treatment of patients with Cushing's disease (CD) who do no...
We conducted a budget impact analysis (BIA) from the perspective of the Brazilian SUS over a 5-year time horizon. We compared two scenarios: ketoconazole (Scenario 1) versus including cabergoline as a...
The total costs were BRL $25,596,729 for Scenario 1 and BRL $32,469,169 for Scenario 2. The budget impact of adding cabergoline to the formulary for CD treatment within the SUS would be BRL $6,091,036...
The estimated budget impact of adding cabergoline to the formulary for CD treatment within the Brazilian SUS would be about BRL $6 million. While cost savings cannot be expected, the budget impact of ...
A 60-year-old patient, professor of physics, presented in 1999 with sudden-onset vitiligo associated with hyperprolactinemia and a prolactinoma. Fearful of potential surgical complications at the peak...
Prolactinomas are rare in children and adolescents. As in adults, dopamine agonists (DAs) are the treatment of choice in the majority of patients. However, at what point children should be taken off o...
Our objective was to systematically review our experience with DA treatment withdrawal in children and adolescents with prolactinomas....
A retrospective review of patients followed for prolactinomas during the last 12 years was conducted. Variables analyzed included age, gender, initial serum prolactin levels, tumor characteristics, ca...
Of 47 patients identified, 42 were included in the study. Of those, DA withdrawal was attempted in 13 (31%) and was initially successful in 3 (21%). Patients who did not meet eligibility criteria for ...
Less than half of our patients were eligible for DA treatment withdrawal and less than one-fourth achieved remission of hyperprolactinemia following cessation of therapy. This suggests that the overal...
Prolactin (PRL)-secreting tumors are the most common functional pituitary adenomas. They usually respond to dopamine agonist (DA) treatment, with PRL normalization and adenoma shrinkage. Our aim was t...
This retrospective case series included patients diagnosed with DA-resistant prolactinomas between 1993-2017 in three medical centers. Resistance was defined as PRL levels above three times the upper ...
Twenty-six patients were identified; 20 males. Of 25 macroadenomas, three were giant tumors (>40 mm) and 15 (57.7%) were invasive. The mean age at diagnosis was 31.8 ± 14.9 years (range: 13-62). The m...
Resistant prolactinomas usually require a multi-modal treatment strategy. We were able to control 14/25 (56%) of resistant tumors....